Evaluation of the HER/PI3K/AKT family signaling network as a predictive biomarker of pathologic complete response for patients with breast cancer treated with Neratinib in the I-SPY 2 TRIAL

Julia D. Wulfkuhle, Christina Yau, Denise M. Wolf, Daniel J. Vis, Rosa I. Gallagher, Lamorna Brown-Swigart, Gillian Hirst, Emile E. Voest, Angela DeMichele, Nola Hylton, Fraser Symmans, Douglas Yee, Laura Esserman, Donald Berry, Minetta Liu, John W. Park, Lodewyk F.A. Wessels, Laura van't Veer, Emanuel F. Petricoin

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Fingerprint

Dive into the research topics of 'Evaluation of the HER/PI3K/AKT family signaling network as a predictive biomarker of pathologic complete response for patients with breast cancer treated with Neratinib in the I-SPY 2 TRIAL'. Together they form a unique fingerprint.

Medicine & Life Sciences